Brief Report: Changes in Plasma RANKL-Osteoprotegerin in a Prospective, Randomized Clinical Trial of Initial Antiviral Therapy: A5260s
| Autor: | Kelesidis, Theodoros, Moser, Carlee B, Johnston, Elizabeth, Stein, James H, Dube, Michael P, Yang, Otto O, McComsey, Grace A, Currier, Judith S, Brown, Todd T |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Clinical Trials and Supportive Activities Clinical Sciences HIV Infections Clinical Research Virology Humans Prospective Studies Prevention RANK Ligand Osteoprotegerin RANKL Evaluation of treatments and therapeutic interventions HIV Middle Aged CVD Infectious Diseases Good Health and Well Being 6.1 Pharmaceuticals Musculoskeletal Public Health and Health Services HIV/AIDS Osteoporosis bone disease Female OPG Infection |
| Zdroj: | Journal of acquired immune deficiency syndromes (1999), vol 78, iss 3 |
| Popis: | BackgroundThe contributions of the receptor activator of nuclear factor kappa-B ligand (RANKL)/osteoprotegerin (OPG) axis to cardiovascular and bone disease in treated HIV-1 infection are not well defined.SettingProspective, observational, longitudinal study.MethodsIn a subset analysis of a prospective randomized clinical trial, 234 HIV-1-infected antiretroviral therapy-naive participants received tenofovir-emtricitabine plus either atazanavir/ritonavir, darunavir/ritonavir, or raltegravir and achieved plasma HIV-1 RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|